DKDaniel KuritzkesMDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Therapies for Emerging Infections Insights from COVID-19 - Daniel KuritzkesView Slideset
CFCharles FlexnerMDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Anti-Infectives Where Do We Stand - Charles FlexnerView Slideset
FVFrançois VenterMD, FCP, PhDSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Anti-Infectives in Resource-Limited Settings - François VenterView Slideset
KSKimberly ScarsiPharmD, MS, FCCPSlideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Clinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis - Kimberly ScarsiView Slideset
GTGrant TheronBSc, MSc, PhDSlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Recent Developments in TB Testing and Screening Technologies, Including for HIV-associated TB and TB in Children - Grant Theron - SlidesetView Slideset
GTGrant TheronBSc, MSc, PhDVideoTuberculosis2nd Conference on Innovations in Tuberculosis 2025Recent Developments in TB Testing and Screening Technologies, Including for HIV-associated TB and TB in Children - Grant TheronView Video
Abstract17th International Workshop on Pediatrics & HIV 2025(Abstract) #23 Association Between Reservoir Size and Markers of Cardiovascular Inflammation in Perinatally Infected Children Living with HIVView Abstract
Abstract17th International Workshop on Pediatrics & HIV 2025(Abstract) #22 Causes of Death among Sub-Saharan African Infants Living with HIV and Hospitalised with Severe Pneumonia Using Minimally Invasive Autopsies in the EMPIRICAL TrialView Abstract
Abstract17th International Workshop on Pediatrics & HIV 2025(Abstract) #21 Switching Off Dolutegravir in Pregnancy During the Safety Signal Period: A Multi-Cohort European StudyView Abstract
Abstract17th International Workshop on Pediatrics & HIV 2025(Abstract) #20 Telomere Length and Neurodevelopmental Outcomes among Children Exposed and Not Exposed to HIV in KenyaView Abstract
Abstract17th International Workshop on Pediatrics & HIV 2025(Abstract) #19 Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY TrialView Abstract
